4DMedical Receives $1.9 Million Grant to Expand Trials for Advanced Lung Imaging Technology

Highlights:

• 4DMedical Ltd (ASX:4DX) has secured $1.9 million from the Australian Federal Government to expand clinical trials for its CT:VQ lung imaging technology.
• The CT:VQ technology enables the measurement of airflow and blood flow in the lungs without using radioactive tracers, offering a safer and cost-effective alternative to nuclear medicine VQ scans.
• With a market potential of over $1 billion in the U.S., the trials aim to replace traditional VQ scans, enhancing diagnostics in respiratory care.

4DMedical Ltd (ASX:4DX), an Australian medical technology company, has been awarded a $1.9 million grant from the Federal Government under its Cooperative Research Centres Projects (CRC-P) program. The funding will support the expansion of clinical trials for 4DMedical’s CT:VQ technology, an innovative lung imaging system that could revolutionize the diagnosis of respiratory conditions. 

This project, titled “CT:VQ – A Better Pulmonary Perfusion Test,” involves collaboration with I-MED, Australia’s largest medical imaging provider, and Macquarie University. The goal is to advance the clinical trials and potentially commercialize CT:VQ as a safer and more cost-effective alternative to current imaging methods used in lung diagnostics. 

The Technology Behind CT:VQ 

CT:VQ stands out due to its ability to measure two critical aspects of lung function—ventilation (V), which refers to airflow, and perfusion (Q), or blood flow. This diagnostic tool extracts this data directly from a CT scan without the need for radioactive tracers or contrast agents, making it both safer and more accessible for patients.  

Nuclear medicine VQ scans, currently the industry standard, rely on radioactive materials to evaluate airflow and blood flow within the lungs. These scans are commonly used to diagnose conditions such as pulmonary embolism, a blockage in the arteries of the lungs. However, nuclear VQ imaging comes with risks due to radiation exposure, high costs, and logistical challenges associated with handling radioactive substances. 

CT:VQ aims to eliminate these hurdles by providing a non-invasive alternative. This technology could enable physicians to assess lung function with greater ease, potentially transforming respiratory diagnostics. 

Expanding Clinical Trials 

The clinical trials for CT:VQ are crucial in gathering the necessary evidence to establish its effectiveness as a viable substitute for nuclear medicine VQ scans. With the financial backing of the Federal Government, 4DMedical plans to expand these trials in collaboration with I-MED and Macquarie University. 

The U.S. market for nuclear medicine VQ scans is particularly substantial, with over one million scans conducted annually. Each test costs more than $1,000, making the market size for this diagnostic method exceed $1 billion. CT:VQ’s potential to replace these tests could significantly reduce costs and improve accessibility in lung diagnostics. 

Managing Director and CEO Andreas Fouras emphasized the transformative potential of CT:VQ, describing it as a "once in a generation opportunity" to disrupt the respiratory diagnostics market. The new funding will allow 4DMedical to propel its research and development efforts, moving closer to commercializing the technology. 

Benefits of CT:VQ Technology 

CT:VQ has several advantages over traditional nuclear medicine VQ scans: 

- Safety: Unlike nuclear scans, CT:VQ does not expose patients to radioactive substances, reducing health risks, particularly for vulnerable populations. 

- Cost-Effectiveness: The technology offers a more affordable solution for healthcare providers and patients, which could lower the overall costs of diagnosing lung conditions. 

- Convenience: CT:VQ is quicker and easier to administer than nuclear scans, improving patient throughput in hospitals and clinics. 

- Accessibility: Eliminating the need for radioactive tracers makes the technology more widely available, especially in areas where nuclear medicine facilities are limited. 

Market Potential and Future Outlook 

As 4DMedical continues to advance its clinical trials, the potential for CT:VQ to replace nuclear medicine VQ scans presents significant opportunities. With a multi-billion dollar market at stake, particularly in the U.S., the company is positioning itself to become a leader in respiratory diagnostics. 

The grant from the Australian government not only validates the promise of CT:VQ but also accelerates its journey toward commercialization. If successful, this technology could be implemented across hospitals worldwide, offering a safer and more efficient diagnostic tool for lung conditions. 

The next steps for 4DMedical will focus on gathering further clinical evidence, scaling up its trials, and ultimately achieving regulatory approvals to bring CT:VQ to market. In doing so, the company aims to improve patient outcomes and enhance the overall efficiency of healthcare systems globally. 

CT:VQ is poised to reshape the landscape of respiratory diagnostics by offering an innovative alternative to existing methods. Through government support and collaborative efforts, 4DMedical continues to move toward a future where safer, faster, and more affordable lung imaging becomes the standard in healthcare.